Characterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients with chronic hepatitis

Página do item simplificado
dc.contributorSistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.authorSANTOS, Ana Paula de Torres
dc.contributor.authorSILVA, Vanessa Cristina Martins
dc.contributor.authorMENDES-CORREA, Maria Cassia
dc.contributor.authorLEMOS, Marcilio Figueiredo
dc.contributor.authorMALTA, Fernanda de Mello
dc.contributor.authorSANTANA, Rubia Anita Ferraz
dc.contributor.authorDASTOLI, Gregorio Tadeu Fernando
dc.contributor.authorCASTRO, Vanessa Fusco Duarte de
dc.contributor.authorPINHO, Joao Renato Rebello
dc.contributor.authorMOREIRA, Regina Celia
dc.date.accessioned2022-12-21T13:23:08Z
dc.date.available2022-12-21T13:23:08Z
dc.date.issued2022
dc.description.abstractThe Hepatitis C virus (HCV) infection is a public health problem. The high level of HCV replication and its lack of post-transcriptional correction mechanisms results in the emergence of viral variants and the difficulty in determining polymorphisms and variants that contain the substitutions associated with resistance towards new antivirals. The main focus of this study was to map the NS5A and NS5B polymorphisms and resistance mutations to new antiviral drugs in HCV strains genotype 1 from patients with chronic hepatitis C infection. Serum samples were collected from patients who underwent routine viral load tests at the Instituto Adolfo Lutz, Sao Paulo city, Brazil. A total of 698 and 853 samples were used for the characterization of NS5A and NS5B regions, respectively, which comprise the HCV genotypes la and lb. The prevalence of resistance mutations found in the NS5A region was 6.4%, with Y93H, L31M, Q30R, and Y93N as the main resistance-associated substitutions (RAS). No NS5B-associated RAS was observed for any of the analyzed drugs. These findings support that the RAS test should be offered to individuals with poor response to double combination regimens prior to treatment initiation, thereby assisting strain vigilance and selection of effective treatment or retreatment options using DAA regimens.eng
dc.description.indexMEDLINEeng
dc.description.sponsorshipFundacao de Amparo a Pesquisa do Estado de Sao Paulo [2017/01809-9 2020/12529-0]
dc.identifier.citationREVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO, v.64, article ID e61, 9p, 2022
dc.identifier.doi10.1590/S1678-9946202264061
dc.identifier.eissn1678-9946
dc.identifier.issn0036-4665
dc.identifier.urihttps://observatorio.fm.usp.br/handle/OPI/50561
dc.language.isoeng
dc.publisherINST MEDICINA TROPICAL SAO PAULOeng
dc.relation.ispartofRevista do Instituto de Medicina Tropical de Sao Paulo
dc.rightsopenAccesseng
dc.rights.holderCopyright INST MEDICINA TROPICAL SAO PAULOeng
dc.subjectDAAeng
dc.subjectHepatitis C viruseng
dc.subjectGenotype 1eng
dc.subjectRASeng
dc.subjectNS5Beng
dc.subjectNS5Aeng
dc.subject.otherhcveng
dc.subject.othersubstitutionseng
dc.subject.otherepidemiologyeng
dc.subject.otherinhibitorseng
dc.subject.othervariantseng
dc.subject.otherimpacteng
dc.subject.wosInfectious Diseaseseng
dc.subject.wosParasitologyeng
dc.subject.wosTropical Medicineeng
dc.titleCharacterization of primary direct-acting antiviral (DAA) drugs resistance mutations in NS5A/NS5B regions of hepatitis C virus with genotype 1a and 1b from patients with chronic hepatitiseng
dc.typearticleeng
dc.type.categoryoriginal articleeng
dc.type.versionpublishedVersioneng
dspace.entity.typePublication
hcfmusp.author.externalSILVA, Vanessa Cristina Martins:Adolfo Lutz Inst, Ctr Virol, Lab Hepatites Virais, Sao Paulo, SP, Brazil
hcfmusp.author.externalLEMOS, Marcilio Figueiredo:Adolfo Lutz Inst, Ctr Virol, Lab Hepatites Virais, Sao Paulo, SP, Brazil
hcfmusp.author.externalSANTANA, Rubia Anita Ferraz:Hosp Israelita Albert Einstein, Med Diagnost, Sao Paulo, SP, Brazil
hcfmusp.author.externalDASTOLI, Gregorio Tadeu Fernando:Hosp Israelita Albert Einstein, Med Diagnost, Sao Paulo, SP, Brazil
hcfmusp.author.externalCASTRO, Vanessa Fusco Duarte de:Hosp Israelita Albert Einstein, Med Diagnost, Sao Paulo, SP, Brazil
hcfmusp.author.externalMOREIRA, Regina Celia:Adolfo Lutz Inst, Ctr Virol, Lab Hepatites Virais, Sao Paulo, SP, Brazil
hcfmusp.citation.scopus1
hcfmusp.contributor.author-fmusphcANA PAULA DE TORRES SANTOS
hcfmusp.contributor.author-fmusphcMARIA CASSIA JACINTHO MENDES CORREA
hcfmusp.contributor.author-fmusphcFERNANDA DE MELLO MALTA
hcfmusp.contributor.author-fmusphcJOAO RENATO REBELLO PINHO
hcfmusp.description.articlenumbere61
hcfmusp.description.volume64
hcfmusp.origemWOS
hcfmusp.origem.pubmed36197422
hcfmusp.origem.scieloSCIELO:S0036-46652022000100233
hcfmusp.origem.scopus2-s2.0-85139156396
hcfmusp.origem.wosWOS:000874034100007
hcfmusp.publisher.citySAO PAULOeng
hcfmusp.publisher.countryBRAZILeng
hcfmusp.relation.referenceAguiar BF, 2020, CLIN RES HEPATOL GAS, V44, P329, DOI 10.1016/j.clinre.2019.07.015eng
hcfmusp.relation.referenceAldunate F, 2018, DIS MARKERS, V2018, DOI 10.1155/2018/2514901eng
hcfmusp.relation.referenceAndre-Garnier E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179562eng
hcfmusp.relation.referenceBhattacharjee Chayan, 2021, VirusDisease, V32, DOI 10.1007/s13337-021-00697-0eng
hcfmusp.relation.referenceBlach S, 2022, LANCET GASTROENTEROL, V7, P396, DOI 10.1016/S2468-1253(21)00472-6eng
hcfmusp.relation.referenceBorgia SM, 2018, J INFECT DIS, V218, P1722, DOI 10.1093/infdis/jiy401eng
hcfmusp.relation.referenceBrasil. Ministerio da Saude, 2015, DEP VIG PREV CONTR Ieng
hcfmusp.relation.referenceCampiotto S, 2005, BRAZ J MED BIOL RES, V38, P41, DOI 10.1590/S0100-879X2005000100007eng
hcfmusp.relation.referenceChen CY, 2021, LIVER INT, V41, P1265, DOI 10.1111/liv.14849eng
hcfmusp.relation.referenceCheng GF, 2016, ANTIMICROB AGENTS CH, V60, P1847, DOI 10.1128/AAC.02524-15eng
hcfmusp.relation.referenceCosta VD, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216327eng
hcfmusp.relation.referenceCuypers L, 2016, REV MED VIROL, V26, P408, DOI 10.1002/rmv.1895eng
hcfmusp.relation.referenceSantos APD, 2021, INFECT DRUG RESIST, V14, P723, DOI 10.2147/IDR.S247071eng
hcfmusp.relation.referenceDi Maio VC, 2021, LIVER INT, V41, P1802, DOI 10.1111/liv.14797eng
hcfmusp.relation.referenceDi Stefano M, 2021, NEW MICROBIOL, V44, P12eng
hcfmusp.relation.referenceEltahla AA, 2017, SCI REP-UK, V7, DOI 10.1038/srep41719eng
hcfmusp.relation.referenceEsposito I, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11010003eng
hcfmusp.relation.referenceFoster GR, 2016, J HEPATOL, V64, P1224, DOI 10.1016/j.jhep.2016.01.029eng
hcfmusp.relation.referenceGottwein JM, 2018, GASTROENTEROLOGY, V154, P1435, DOI 10.1053/j.gastro.2017.12.015eng
hcfmusp.relation.referenceGower E, 2014, J HEPATOL, V61, pS45, DOI 10.1016/j.jhep.2014.07.027eng
hcfmusp.relation.referenceJimenez-Perez M, 2016, WORLD J GASTROENTERO, V22, P6573, DOI 10.3748/wjg.v22.i29.6573eng
hcfmusp.relation.referenceKalaghatgi P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155869eng
hcfmusp.relation.referenceLavanchy D, 2011, CLIN MICROBIOL INFEC, V17, P107, DOI 10.1111/j.1469-0691.2010.03432.xeng
hcfmusp.relation.referenceLiu ZQ, 2020, J VIRAL HEPATITIS, V27, P585, DOI 10.1111/jvh.13270eng
hcfmusp.relation.referenceMalta F, 2017, BMC INFECT DIS, V17, DOI 10.1186/s12879-017-2817-7eng
hcfmusp.relation.referenceMeshram RJ, 2022, ARCH VIROL, V167, P717, DOI 10.1007/s00705-022-05375-0eng
hcfmusp.relation.referenceNoble CF, 2017, ARCH VIROL, V162, P165, DOI 10.1007/s00705-016-3094-2eng
hcfmusp.relation.referencePeres-da-Silva A, 2015, J ANTIMICROB CHEMOTH, V70, P726, DOI 10.1093/jac/dku462eng
hcfmusp.relation.referenceRao HY, 2020, J CLIN TRANSL HEPATO, V8, P255, DOI 10.14218/JCTH.2020.00031eng
hcfmusp.relation.referenceSagnelli E, 2018, INFECTION, V46, P761, DOI 10.1007/s15010-018-1188-3eng
hcfmusp.relation.referenceSandres-Saune K, 2003, J VIROL METHODS, V109, P187, DOI 10.1016/S0166-0934(03)00070-3eng
hcfmusp.relation.referenceSANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463eng
hcfmusp.relation.referenceSarrazin C, 2016, J HEPATOL, V64, P486, DOI 10.1016/j.jhep.2015.09.011eng
hcfmusp.relation.referenceSarrazin C, 2014, Z GASTROENTEROL, V52, P1185, DOI 10.1055/s-0033-1362816eng
hcfmusp.relation.referenceSayan M, 2020, INT J INFECT DIS, V95, P84, DOI 10.1016/j.ijid.2020.03.061eng
hcfmusp.relation.referenceSharafi H, 2018, WORLD J HEPATOL, V10, P543, DOI 10.4254/wjh.v10.i9.543eng
hcfmusp.relation.referenceSimmonds P, 2005, HEPATOLOGY, V42, P962, DOI 10.1002/hep.20819eng
hcfmusp.relation.referenceSorbo MC, 2018, DRUG RESIST UPDATE, V37, P17, DOI 10.1016/j.drup.2018.01.004eng
hcfmusp.relation.referenceSuzuki F, 2012, J CLIN VIROL, V54, P352, DOI 10.1016/j.jcv.2012.04.024eng
hcfmusp.relation.referenceWyles David L, 2017, Top Antivir Med, V25, P103eng
hcfmusp.scopus.lastupdate2024-04-12
relation.isAuthorOfPublication427daac2-b71c-4ac4-984f-1531a0c1460f
relation.isAuthorOfPublication4ec4044d-75d1-4d30-8176-efd04b22c8d6
relation.isAuthorOfPublicationa9324386-13b6-4aae-8f0c-8273588275c3
relation.isAuthorOfPublication0ada2eb1-5ac2-4e40-b4e2-6af14f33268b
relation.isAuthorOfPublication.latestForDiscovery427daac2-b71c-4ac4-984f-1531a0c1460f
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
art_SANTOS_Characterization_of_primary_directacting_antiviral_DAA_drugs_resistance_2022.PDF
Tamanho:
214.2 KB
Formato:
Adobe Portable Document Format
Descrição:
publishedVersion (English)
Baixar
Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - IMT
Artigos e Materiais de Revistas Científicas - LIM/07
Artigos e Materiais de Revistas Científicas - LIM/52
Artigos e Materiais de Revistas Científicas - ODS/03